Volume : 11, Issue : 09, September – 2024
Title:
BASED ON STUDY OF TIRZEPATIDE IN THE MANAGEMENT OF CHRONIC WEIGHT LOSS IN TYPE 2 DIABETES
Authors :
Kattepogu Naga Kumari, Sakila Jayasri*, Vinjamuri Glory Nissy*
Abstract :
The present study indicates that the Tirzepatide is a promising drug with dual acting glucose dependent insulin tropic polypeptide peptide and glucagon like peptide receptor activation that has revolutionized the treatment of type 2 diabetes mellitus. Tirzepatide is indicated to improve blood sugar control in adults with type 2diabetes as an additional to diet and exercise. It is also indicated as an adjunct to reduced calorie diet and increased physical activity for chronic weight management. Tirzepatide has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction in a phase 3 trail.
Over two years,Tirzepatide reduced the risk of major complications including urgent heart failure visits, hospitalizations, increased diuretic treatment and cardiovascular related deaths by 38% compared to placebo.This makes Tirzepatide has been shown to achieve better glycemic control in terms of glycosylated hemoglobin reduction and improve fasting and post pride in a glucose levels as combined with other diabetic medications.Tirzepatide has acceptable side effects in this well tolerated with lower risk of hyperglycemia . In this review we have summarized the clinical trials and their respective outcomes in highlighted the potential future indications for tirzepatide in the management of obesity, heart failure, non alcoholic steatohepatitis. (1)
Key Words: Tirzepatide, type 2 diabetes mellitus, chronic weight management, benefits in obese patients with a common type of heart failure, preserved ejection fraction in a phase 3 trail.
Cite This Article:
Please cite this article in press Kattepogu Naga Kumari et al., Based On Study Of Tirzepatide In The Management Of Chronic Weight Loss In Type 2 Diabetes., Indo Am. J. P. Sci, 2024; 11 (09).
Number of Downloads : 10
References:
1. Farzam K, Patel P. Vol. 27. Treasure Island (FL): Stat Pearls Publishing; December: In: StatPearls; 2022. FDA approves novel, dual-targeted treatment for type 2 diabetes; p. 2022. [Google Scholar].
2. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Molecules. 2022; 27:4315. [PMC free article] [PubMed] [Google Scholar].
3. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Finan B, Ma T, Ottaway N, et al. Sci Transl Med. 2013;5:209. [PubMed] [Google Scholar].
4. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ. Gastroenterology. 2007;132:2131–2157. [PubMed] [Google Scholar].
5. Tirzepatide – a dual GIP/GLP-1 receptor agonist – a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Nowak M, Nowak W, Grzeszczak W. Endokrynol Pol. 2022;73:745–755. [PubMed] [Google Scholar].
6. How may GIP enhance the therapeutic efficacy of GLP-1? Samms RJ, Coghlan MP, Sloop KW. Trends Endocrinol Metab. 2020; 31:410–421. [PubMed] [Google Scholar].
7. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP, Nauck MA, Van J, et al. Lancet. 2018;392:2180–2193. [PubMed] [Google Scholar].
8. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385:503–515. [PubMed] [Google Scholar].
9. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Ludvik B, Giorgino F, Jódar E, et al. Lancet. 2021;398:583–598. [PubMed] [Google Scholar].
10. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Del Prato S, Kahn SE, Pavo I, et al. Lancet. 2021;398:1811–1824. [PubMed] [Google Scholar].
11. Plasma insulin response to oral and intravenous glucose administration. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. J Clin Endocrinol Metab. 1964;24:1076–1082. [PubMed] [Google Scholar].
12. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. J Clin Endocrinol Metab. 1986;63:492–498. [PubMed] [Google Scholar].
13. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Nauck MA, Meier JJ. Lancet Diabetes Endocrinol. 2016;4:525–536. [PubMed] [Google Scholar].
14. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, Knop FK. Diabetologia. 2013;56:965–972. [PMC free article] [PubMed] [Google Scholar].